Clinical trial
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After…
NCT00424255 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00424255 |
|---|---|
| Title | Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery |
| Official title | A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects With Resected Squamous Cell Carcinoma of the Head and Neck… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Head and Neck |
| Intervention type | Drug, Other, Radiation |
| Interventions | Lapatinib, Chemoradiation, Placebo |
| Enrollment | 688 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2013 |
| Completion | Nov 1, 2013 |
| First posted | Jan 19, 2007 |
| Last update posted | Jul 18, 2014 |
| Countries | Argentina, Austria, Canada, China, Croatia, Czechia, Estonia, France, Germany, Greece, Hong Kong, Hungary and 10 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: